Short Wave Pharma, a biopharmaceutical company developing patent pending psychedelic compositions and methods of delivery, has signed a clinical trial agreement  with the Sheba Fund for Health Services and Research and with Dr. Eitan Gur, Principal Investigator and Head of the Sheba Medical Center Department for Eating Disorders and Golbert, Co–Investigator at the Center.

Under the Agreement, Shortwave will be the exclusive commercial partner in an investigator-initiated, open-label, phase II study of the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa. 

The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.

In recognition of its financial support for the Trial, the Company will gain access to the Trial's data as well as a first right of refusal to commercialize any intellectual property generated from the Trial. The parties agree to cooperate in the future, and to positively consider a follow-on study by the Fund and the Center using the Company's psilocybin-based formulation and buccal film delivery system.

Anorexia nervosa is a life-threatening disease and a severe eating disorder that affects about 0.5-1% of the population. Of all psychiatric disorders, anorexia is a leading cause of disability in the U.S. and many other developed countries.